Correction of endocrine complications of oncoimmunotherapy
Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
E. A. Pigarova [verfasserIn] A. S. Shutova [verfasserIn] L. K. Dzeranova [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Russisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Ожирение и метаболизм ; 19(2023), 4, Seite 418-430 volume:19 ; year:2023 ; number:4 ; pages:418-430 |
|---|
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.14341/omet12828 |
|---|
| Katalog-ID: |
DOAJ089202171 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ089202171 | ||
| 003 | DE-627 | ||
| 005 | 20240413141250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230505s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14341/omet12828 |2 doi | |
| 035 | |a (DE-627)DOAJ089202171 | ||
| 035 | |a (DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a QP1-981 | |
| 050 | 0 | |a QD415-436 | |
| 100 | 0 | |a E. A. Pigarova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correction of endocrine complications of oncoimmunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. | ||
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a endocrine autoimmune adverse events | |
| 650 | 4 | |a hypophysitis | |
| 650 | 4 | |a adrenal insufficiency | |
| 650 | 4 | |a central diabetes insipidus | |
| 650 | 4 | |a thyroiditis, hypocalcemia | |
| 650 | 4 | |a hypoparathyroidism | |
| 650 | 4 | |a hyponatremia | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a cancer immunotherapy | |
| 650 | 4 | |a ipilimumab | |
| 650 | 4 | |a nivolumab | |
| 653 | 0 | |a Physiology | |
| 653 | 0 | |a Biochemistry | |
| 700 | 0 | |a A. S. Shutova |e verfasserin |4 aut | |
| 700 | 0 | |a L. K. Dzeranova |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Ожирение и метаболизм |g 19(2023), 4, Seite 418-430 |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:4 |g pages:418-430 |
| 856 | 4 | 0 | |u https://doi.org/10.14341/omet12828 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b |z kostenfrei |
| 856 | 4 | 0 | |u https://www.omet-endojournals.ru/jour/article/view/12828 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2071-8713 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2306-5524 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 4 |h 418-430 | ||
| author_variant |
e a p eap a s s ass l k d lkd |
|---|---|
| matchkey_str |
eapigarovaasshutovalkdzeranova:2023----:orcinfnorncmlctosfn |
| hierarchy_sort_str |
2023 |
| callnumber-subject-code |
QP |
| publishDate |
2023 |
| allfields |
10.14341/omet12828 doi (DE-627)DOAJ089202171 (DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Pigarova verfasserin aut Correction of endocrine complications of oncoimmunotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab Physiology Biochemistry A. S. Shutova verfasserin aut L. K. Dzeranova verfasserin aut In Ожирение и метаболизм 19(2023), 4, Seite 418-430 volume:19 year:2023 number:4 pages:418-430 https://doi.org/10.14341/omet12828 kostenfrei https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b kostenfrei https://www.omet-endojournals.ru/jour/article/view/12828 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2023 4 418-430 |
| spelling |
10.14341/omet12828 doi (DE-627)DOAJ089202171 (DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Pigarova verfasserin aut Correction of endocrine complications of oncoimmunotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab Physiology Biochemistry A. S. Shutova verfasserin aut L. K. Dzeranova verfasserin aut In Ожирение и метаболизм 19(2023), 4, Seite 418-430 volume:19 year:2023 number:4 pages:418-430 https://doi.org/10.14341/omet12828 kostenfrei https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b kostenfrei https://www.omet-endojournals.ru/jour/article/view/12828 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2023 4 418-430 |
| allfields_unstemmed |
10.14341/omet12828 doi (DE-627)DOAJ089202171 (DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Pigarova verfasserin aut Correction of endocrine complications of oncoimmunotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab Physiology Biochemistry A. S. Shutova verfasserin aut L. K. Dzeranova verfasserin aut In Ожирение и метаболизм 19(2023), 4, Seite 418-430 volume:19 year:2023 number:4 pages:418-430 https://doi.org/10.14341/omet12828 kostenfrei https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b kostenfrei https://www.omet-endojournals.ru/jour/article/view/12828 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2023 4 418-430 |
| allfieldsGer |
10.14341/omet12828 doi (DE-627)DOAJ089202171 (DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Pigarova verfasserin aut Correction of endocrine complications of oncoimmunotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab Physiology Biochemistry A. S. Shutova verfasserin aut L. K. Dzeranova verfasserin aut In Ожирение и метаболизм 19(2023), 4, Seite 418-430 volume:19 year:2023 number:4 pages:418-430 https://doi.org/10.14341/omet12828 kostenfrei https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b kostenfrei https://www.omet-endojournals.ru/jour/article/view/12828 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2023 4 418-430 |
| allfieldsSound |
10.14341/omet12828 doi (DE-627)DOAJ089202171 (DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b DE-627 ger DE-627 rakwb eng rus QP1-981 QD415-436 E. A. Pigarova verfasserin aut Correction of endocrine complications of oncoimmunotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab Physiology Biochemistry A. S. Shutova verfasserin aut L. K. Dzeranova verfasserin aut In Ожирение и метаболизм 19(2023), 4, Seite 418-430 volume:19 year:2023 number:4 pages:418-430 https://doi.org/10.14341/omet12828 kostenfrei https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b kostenfrei https://www.omet-endojournals.ru/jour/article/view/12828 kostenfrei https://doaj.org/toc/2071-8713 Journal toc kostenfrei https://doaj.org/toc/2306-5524 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2023 4 418-430 |
| language |
English Russian |
| source |
In Ожирение и метаболизм 19(2023), 4, Seite 418-430 volume:19 year:2023 number:4 pages:418-430 |
| sourceStr |
In Ожирение и метаболизм 19(2023), 4, Seite 418-430 volume:19 year:2023 number:4 pages:418-430 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab Physiology Biochemistry |
| isfreeaccess_bool |
true |
| container_title |
Ожирение и метаболизм |
| authorswithroles_txt_mv |
E. A. Pigarova @@aut@@ A. S. Shutova @@aut@@ L. K. Dzeranova @@aut@@ |
| publishDateDaySort_date |
2023-01-01T00:00:00Z |
| id |
DOAJ089202171 |
| language_de |
englisch russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ089202171</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413141250.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/omet12828</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ089202171</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP1-981</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD415-436</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. A. Pigarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Correction of endocrine complications of oncoimmunotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endocrine autoimmune adverse events</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypophysitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adrenal insufficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">central diabetes insipidus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">thyroiditis, hypocalcemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypoparathyroidism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyponatremia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">diabetes mellitus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ipilimumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nivolumab</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Physiology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biochemistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Shutova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. K. Dzeranova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Ожирение и метаболизм</subfield><subfield code="g">19(2023), 4, Seite 418-430</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:418-430</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/omet12828</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.omet-endojournals.ru/jour/article/view/12828</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2071-8713</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2306-5524</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2023</subfield><subfield code="e">4</subfield><subfield code="h">418-430</subfield></datafield></record></collection>
|
| callnumber-first |
Q - Science |
| author |
E. A. Pigarova |
| spellingShingle |
E. A. Pigarova misc QP1-981 misc QD415-436 misc immune checkpoint inhibitors misc endocrine autoimmune adverse events misc hypophysitis misc adrenal insufficiency misc central diabetes insipidus misc thyroiditis, hypocalcemia misc hypoparathyroidism misc hyponatremia misc diabetes mellitus misc cancer immunotherapy misc ipilimumab misc nivolumab misc Physiology misc Biochemistry Correction of endocrine complications of oncoimmunotherapy |
| authorStr |
E. A. Pigarova |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
QP1-981 |
| illustrated |
Not Illustrated |
| topic_title |
QP1-981 QD415-436 Correction of endocrine complications of oncoimmunotherapy immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab |
| topic |
misc QP1-981 misc QD415-436 misc immune checkpoint inhibitors misc endocrine autoimmune adverse events misc hypophysitis misc adrenal insufficiency misc central diabetes insipidus misc thyroiditis, hypocalcemia misc hypoparathyroidism misc hyponatremia misc diabetes mellitus misc cancer immunotherapy misc ipilimumab misc nivolumab misc Physiology misc Biochemistry |
| topic_unstemmed |
misc QP1-981 misc QD415-436 misc immune checkpoint inhibitors misc endocrine autoimmune adverse events misc hypophysitis misc adrenal insufficiency misc central diabetes insipidus misc thyroiditis, hypocalcemia misc hypoparathyroidism misc hyponatremia misc diabetes mellitus misc cancer immunotherapy misc ipilimumab misc nivolumab misc Physiology misc Biochemistry |
| topic_browse |
misc QP1-981 misc QD415-436 misc immune checkpoint inhibitors misc endocrine autoimmune adverse events misc hypophysitis misc adrenal insufficiency misc central diabetes insipidus misc thyroiditis, hypocalcemia misc hypoparathyroidism misc hyponatremia misc diabetes mellitus misc cancer immunotherapy misc ipilimumab misc nivolumab misc Physiology misc Biochemistry |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Ожирение и метаболизм |
| hierarchy_top_title |
Ожирение и метаболизм |
| isfreeaccess_txt |
true |
| title |
Correction of endocrine complications of oncoimmunotherapy |
| ctrlnum |
(DE-627)DOAJ089202171 (DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b |
| title_full |
Correction of endocrine complications of oncoimmunotherapy |
| author_sort |
E. A. Pigarova |
| journal |
Ожирение и метаболизм |
| journalStr |
Ожирение и метаболизм |
| callnumber-first-code |
Q |
| lang_code |
eng rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| container_start_page |
418 |
| author_browse |
E. A. Pigarova A. S. Shutova L. K. Dzeranova |
| container_volume |
19 |
| class |
QP1-981 QD415-436 |
| format_se |
Elektronische Aufsätze |
| author-letter |
E. A. Pigarova |
| doi_str_mv |
10.14341/omet12828 |
| author2-role |
verfasserin |
| title_sort |
correction of endocrine complications of oncoimmunotherapy |
| callnumber |
QP1-981 |
| title_auth |
Correction of endocrine complications of oncoimmunotherapy |
| abstract |
Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. |
| abstractGer |
Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. |
| abstract_unstemmed |
Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
4 |
| title_short |
Correction of endocrine complications of oncoimmunotherapy |
| url |
https://doi.org/10.14341/omet12828 https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b https://www.omet-endojournals.ru/jour/article/view/12828 https://doaj.org/toc/2071-8713 https://doaj.org/toc/2306-5524 |
| remote_bool |
true |
| author2 |
A. S. Shutova L. K. Dzeranova |
| author2Str |
A. S. Shutova L. K. Dzeranova |
| callnumber-subject |
QP - Physiology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.14341/omet12828 |
| callnumber-a |
QP1-981 |
| up_date |
2024-07-03T21:50:33.829Z |
| _version_ |
1803596263670677504 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ089202171</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413141250.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/omet12828</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ089202171</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcbbf2cbfe27541cf9aaffb38dac00f8b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP1-981</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD415-436</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. A. Pigarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Correction of endocrine complications of oncoimmunotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endocrine autoimmune adverse events</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypophysitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adrenal insufficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">central diabetes insipidus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">thyroiditis, hypocalcemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypoparathyroidism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyponatremia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">diabetes mellitus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ipilimumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nivolumab</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Physiology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biochemistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Shutova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. K. Dzeranova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Ожирение и метаболизм</subfield><subfield code="g">19(2023), 4, Seite 418-430</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:418-430</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/omet12828</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cbbf2cbfe27541cf9aaffb38dac00f8b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.omet-endojournals.ru/jour/article/view/12828</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2071-8713</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2306-5524</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2023</subfield><subfield code="e">4</subfield><subfield code="h">418-430</subfield></datafield></record></collection>
|
| score |
7.4002686 |